Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler Relat Disord
Main Authors: Lucchini, Matteo, Bianco, Assunta, Del Giacomo, Paola, De Fino, Chiara, Nociti, Viviana, Mirabella, Massimiliano
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier B.V. 2020
Assuntos:
Correspondence
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307994/
https://ncbi.nlm.nih.gov/pubmed/32593961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados